Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ORENITRAM safely and effectively. See Full Prescribing Information for ORENITRAM. ORENITRAM® (treprostinil) extended-release tablets, for oral use Initial U.S. Approval: 2002
Medication labelWhy this: Advisory · dailymed-prescription
Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).
- generic_name
- treprostinil
- product_names
- treprostinil
- ndc
- 66302-300, 66302-302, 66302-310, 66302-325, 66302-350, 66302-361, 66302-362, 66302-363, 66302-300-01, 66302-300-10, 66302-300-02, 66302-302-01, 66302-302-10, 66302-302-02, 66302-310-01, 66302-310-10, 66302-310-02, 66302-325-01, 66302-325-10, 66302-325-02, 66302-350-01, 66302-350-10, 66302-350-02, 66302-361-28, 66302-362-56, 66302-363-84
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en